{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:58:45Z","timestamp":1782485925610,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL155000"],"award-info":[{"award-number":["T32HL155000"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F32HL170592"],"award-info":[{"award-number":["F32HL170592"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL167858"],"award-info":[{"award-number":["R01HL167858"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-026-02464-1","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:22:47Z","timestamp":1772896967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel digital twin strategy to examine the implications of randomized clinical trials for real-world populations"],"prefix":"10.1038","volume":"9","author":[{"given":"Phyllis M.","family":"Thangaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumukh Vasisht","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish N.","family":"Nadkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobak J.","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos K.","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"2464_CR1","doi-asserted-by":"publisher","first-page":"103870","DOI":"10.1016\/j.jbi.2021.103870","volume":"121","author":"AJ Averitt","year":"2021","unstructured":"Averitt, A. J., Ryan, P. B., Weng, C. & Perotte, A. A conceptual framework for external validity. J. Biomed. Inform. 121, 103870 (2021).","journal-title":"J. Biomed. Inform."},{"key":"2464_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell, P. M. External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply? Lancet 365, 82\u201393 (2005).","journal-title":"Lancet"},{"key":"2464_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/eurheartj\/ehac810","volume":"44","author":"L Filbey","year":"2023","unstructured":"Filbey, L. et al. Improving representativeness in trials: a call to action from the global cardiovascular clinical trialists forum. Eur. Heart J. 44, 921\u2013930 (2023).","journal-title":"Eur. Heart J."},{"key":"2464_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S. & Johnston, J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16, 495 (2015).","journal-title":"Trials"},{"key":"2464_CR5","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1371\/journal.pmed.0030044","volume":"3","author":"M Ranganathan","year":"2006","unstructured":"Ranganathan, M. & Bhopal, R. Exclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies. PLoS Med. 3, e44 (2006).","journal-title":"PLoS Med."},{"key":"2464_CR6","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1001\/jamainternmed.2014.4758","volume":"174","author":"MR Sardar","year":"2014","unstructured":"Sardar, M. R., Badri, M., Prince, C. T., Seltzer, J. & Kowey, P. R. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern. Med. 174, 1868\u20131870 (2014).","journal-title":"JAMA Intern. Med."},{"key":"2464_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2022.0161","volume":"7","author":"EM DeFilippis","year":"2022","unstructured":"DeFilippis, E. M. et al. Improving enrollment of underrepresented racial and ethnic populations in heart failure trials: a call to action from the heart failure collaboratory. JAMA Cardiol. 7, 540\u2013548 (2022).","journal-title":"JAMA Cardiol."},{"key":"2464_CR8","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1016\/S2589-7500(22)00170-4","volume":"4","author":"EK Oikonomou","year":"2022","unstructured":"Oikonomou, E. K., Spatz, E. S., Suchard, M. A. & Khera, R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. Lancet Digit. Health 4, e796\u2013e805 (2022).","journal-title":"Lancet Digit. Health"},{"key":"2464_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2337\/dc21-1765","volume":"45","author":"EK Oikonomou","year":"2022","unstructured":"Oikonomou, E. K., Suchard, M. A., McGuire, D. K. & Khera, R. Phenomapping-derived tool to individualize the effect of canagliflozin on cardiovascular risk in type 2 diabetes. Diab. Care 45, 965\u2013974 (2022).","journal-title":"Diab. Care"},{"key":"2464_CR10","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1093\/eurheartj\/ehab223","volume":"42","author":"EK Oikonomou","year":"2021","unstructured":"Oikonomou, E. K. et al. A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). Eur. Heart J. 42, 2536\u20132548 (2021).","journal-title":"Eur. Heart J."},{"key":"2464_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cardfail.2017.04.006","volume":"23","author":"HC Patel","year":"2017","unstructured":"Patel, H. C. et al. Assessing the eligibility criteria in phase iii randomized controlled trials of drug therapy in heart failure with preserved ejection fraction: the critical play-off between a \u201cpure\u201d patient phenotype and the generalizability of trial findings. J. Card. Fail. 23, 517\u2013524 (2017).","journal-title":"J. Card. Fail."},{"key":"2464_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/ehjqcco\/qcab070","volume":"8","author":"YMF Lim","year":"2022","unstructured":"Lim, Y. M. F. et al. Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. Eur. Heart J. Qual. Care Clin. Outcomes 8, 761\u2013769 (2022).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"2464_CR13","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SPRINT Research Group","year":"2015","unstructured":"SPRINT Research Group et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103\u20132116 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2464_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"ACCORD Study Group et al.","year":"2010","unstructured":"ACCORD Study Group et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575\u20131585 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2464_CR15","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1056\/NEJMoa2307983","volume":"389","author":"JL Carson","year":"2023","unstructured":"Carson, J. L. et al. Restrictive or liberal transfusion strategy in myocardial infarction and anemia. N. Engl. J. Med. 389, 2446\u20132456 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2464_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jama.2021.0135","volume":"325","author":"G Ducrocq","year":"2021","unstructured":"Ducrocq, G. et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA 325, 552\u2013560 (2021).","journal-title":"JAMA"},{"key":"2464_CR17","doi-asserted-by":"publisher","unstructured":"Joosten, L. P. T. et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066485 (2023).","DOI":"10.1161\/CIRCULATIONAHA.123.066485"},{"key":"2464_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981\u2013992 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2464_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2009.02.010","volume":"63","author":"D Jane-wit","year":"2010","unstructured":"Jane-wit, D., Horwitz, R. I. & Concato, J. Variation in results from randomized, controlled trials: stochastic or systematic? J. Clin. Epidemiol. 63, 56\u201363 (2010).","journal-title":"J. Clin. Epidemiol."},{"key":"2464_CR20","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/ajh\/hpw065","volume":"29","author":"LR Krakoff","year":"2016","unstructured":"Krakoff, L. R. A tale of 3 trials: ACCORD, SPRINT, and SPS3. What happened? Am. J. Hypertens. 29, 1020\u20131023 (2016).","journal-title":"Am. J. Hypertens."},{"key":"2464_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jama.2017.0105","volume":"317","author":"AV Chobanian","year":"2017","unstructured":"Chobanian, A. V. Hypertension in 2017-what is the right target? JAMA 317, 579\u2013580 (2017).","journal-title":"JAMA"},{"key":"2464_CR22","doi-asserted-by":"crossref","unstructured":"Huang, C. et al. Systolic blood pressure response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to control cardiovascular risk in diabetes): a possible explanation for discordant trial results. J. Am. Heart Assoc. 6, e007509 (2017).","DOI":"10.1161\/JAHA.117.007509"},{"key":"2464_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/2047487318815967","volume":"26","author":"LJ Laffin","year":"2019","unstructured":"Laffin, L. J., Besser, S. A. & Alenghat, F. J. A data-zone scoring system to assess the generalizability of clinical trial results to individual patients. Eur. J. Prev. Cardiol. 26, 569\u2013575 (2019).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2464_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","volume":"592","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592, 629\u2013633 (2021).","journal-title":"Nature"},{"key":"2464_CR25","doi-asserted-by":"publisher","first-page":"585804","DOI":"10.3389\/fgene.2020.585804","volume":"11","author":"Q Ge","year":"2020","unstructured":"Ge, Q. et al. Conditional generative adversarial networks for individualized treatment effect estimation and treatment selection. Front. Genet. 11, 585804 (2020).","journal-title":"Front. Genet."},{"key":"2464_CR26","unstructured":"Yoon, J., Jordon, J. & Van Der Schaar, M. Ganite: estimation of individualized treat- ment effects using generative adversarial nets. https:\/\/openreview.net\/pdf?id=ByKWUeWA- (2018)."},{"key":"2464_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41746-023-00834-7","volume":"6","author":"J Li","year":"2023","unstructured":"Li, J., Cairns, B. J., Li, J. & Zhu, T. Generating synthetic mixed-type longitudinal electronic health records for artificial intelligent applications. NPJ Digit. Med. 6, 98 (2023).","journal-title":"NPJ Digit. Med."},{"key":"2464_CR28","doi-asserted-by":"publisher","unstructured":"Xu, L., Skoularidou, M., Cuesta-Infante, A. & Veeramachaneni, K. Modeling tabular data using conditional GAN. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1907.00503 (2019).","DOI":"10.48550\/arXiv.1907.00503"},{"key":"2464_CR29","doi-asserted-by":"publisher","unstructured":"Lederrey, G., Hillel, T. & Bierlaire, M. ciDATGAN: conditional inputs for tabular GANs. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2210.02404 (2022).","DOI":"10.48550\/arXiv.2210.02404"},{"key":"2464_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/cts.12764","volume":"13","author":"Z He","year":"2020","unstructured":"He, Z. et al. Clinical trial generalizability assessment in the big data era: a review. Clin. Transl. Sci. 13, 675\u2013684 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"2464_CR31","doi-asserted-by":"publisher","first-page":"c322","DOI":"10.1159\/000319591","volume":"116","author":"G Tripepi","year":"2010","unstructured":"Tripepi, G., Jager, K. J., Dekker, F. W. & Zoccali, C. Stratification for confounding\u2013part 2: direct and indirect standardization. Nephron Clin. Pract. 116, c322\u2013c325 (2010).","journal-title":"Nephron Clin. Pract."},{"key":"2464_CR32","doi-asserted-by":"publisher","first-page":"e005010","DOI":"10.1161\/CIRCOUTCOMES.118.005010","volume":"12","author":"T Duan","year":"2019","unstructured":"Duan, T., Rajpurkar, P., Laird, D., Ng, A. Y. & Basu, S. Clinical value of predicting individual treatment effects for intensive blood pressure therapy. Circ. Cardiovasc. Qual. Outcomes 12, e005010 (2019).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"2464_CR33","doi-asserted-by":"publisher","unstructured":"Brantner, C. L. et al. Comparison of methods that combine multiple randomized trials to estimate heterogeneous treatment effects. Stat. Med. https:\/\/doi.org\/10.1002\/sim.9955 (2024).","DOI":"10.1002\/sim.9955"},{"key":"2464_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annepidem.2021.07.003","volume":"65","author":"S Raghavan","year":"2022","unstructured":"Raghavan, S. et al. Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control. Ann. Epidemiol. 65, 101\u2013108 (2022).","journal-title":"Ann. Epidemiol."},{"key":"2464_CR35","doi-asserted-by":"crossref","unstructured":"Fisher, C. K., Smith, A. M., Walsh, J. R., Coalition Against Major Diseases & Abbott, Alliance for Aging Research, Alzheimer\u2019s Association, Alzheimer\u2019s Foundation of America, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech, Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals Corporation, Parkinson\u2019s Action Network, Parkinson\u2019s Disease Foundation, Pfizer, Inc., sanofi-aventis, Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC), Ephibian & Metrum Institute. Machine learning for comprehensive forecasting of Alzheimer\u2019s Disease progression. Sci. Rep. 9, 13622 (2019).","DOI":"10.1038\/s41598-019-49656-2"},{"key":"2464_CR36","doi-asserted-by":"publisher","unstructured":"Walsh, J. R. et al. Generating digital twins with multiple sclerosis using probabilistic neural networks. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2002.02779 (2020).","DOI":"10.48550\/arXiv.2002.02779"},{"key":"2464_CR37","doi-asserted-by":"publisher","unstructured":"Bertolini, D. et al. Modeling disease progression in mild cognitive impairment and Alzheimer\u2019s disease with digital twins. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2012.13455 (2020).","DOI":"10.48550\/arXiv.2012.13455"},{"key":"2464_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41746-024-01076-x","volume":"7","author":"J-N Eckardt","year":"2024","unstructured":"Eckardt, J.-N. et al. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence. NPJ Digit. Med. 7, 76 (2024).","journal-title":"NPJ Digit. Med."},{"key":"2464_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1146\/annurev-statistics-042522-103837","volume":"10","author":"I Degtiar","year":"2023","unstructured":"Degtiar, I. & Rose, S. A review of generalizability and transportability. Annu. Rev. Stat. Appl. 10, 501\u2013524 (2023).","journal-title":"Annu. Rev. Stat. Appl."},{"key":"2464_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet 404, 245\u2013255 (2024).","journal-title":"Lancet"},{"key":"2464_CR41","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) U.S. Food and Drug Administration. Framework for FDA\u2019s Real World Evidence Program. US Food & Drug Administration https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence (2018)."},{"key":"2464_CR42","doi-asserted-by":"publisher","unstructured":"Lederrey, G., Hillel, T. & Bierlaire, M. DATGAN: integrating expert knowledge into deep learning for synthetic tabular data. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2203.03489 (2022).","DOI":"10.48550\/arXiv.2203.03489"},{"key":"2464_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057977","volume":"12","author":"R Khera","year":"2022","unstructured":"Khera, R. et al. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open 12, e057977 (2022).","journal-title":"BMJ Open"},{"key":"2464_CR44","unstructured":"Goodfellow, I. J. et al. Generative adversarial networks. Generative Adversarial Nets. Advances in Neural Information Processing Systems; Curran Associates, Inc. (2014)"},{"key":"2464_CR45","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1162\/neco.1997.9.8.1735","volume":"9","author":"S Hochreiter","year":"1997","unstructured":"Hochreiter, S. & Schmidhuber, J. Long short-term memory. Neural Comput. 9, 1735\u20131780 (1997).","journal-title":"Neural Comput."},{"key":"2464_CR46","unstructured":"Zhao, Z., Kunar, A., Van der Scheer, H., Birke, R. & Chen, L. Y. Ctab-gan: Eff ective table data synthesizing. In Proc. 13th Asian Conference on Machine Learning, Vol. 157, 97\u2013112 (2021)."},{"key":"2464_CR47","unstructured":"Arjovsky, M., Chintala, S. & Bottou, L. In Proc. 34th International Conference on Machine Learning, Vol. 70, 214\u2013223 (PMLR, 2017)."},{"key":"2464_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","volume":"54","author":"ST Normand","year":"2001","unstructured":"Normand, S. T. et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J. Clin. Epidemiol. 54, 387\u2013398 (2001).","journal-title":"J. Clin. Epidemiol."},{"key":"2464_CR49","doi-asserted-by":"crossref","unstructured":"Patki, N., Wedge, R. & Veeramachaneni, K. The synthetic data vault. In Proc. 2016 IEEE International Conference on Data Science and Advanced Analytics (DSAA) (IEEE, 2016).","DOI":"10.1109\/DSAA.2016.49"},{"key":"2464_CR50","doi-asserted-by":"crossref","unstructured":"Zhao Z., Kunar A., Birke R., Van der Scheer, H. & Chen, L.Y. CTAB-GAN+: enhancing tabular data synthesis. Front. Big Data 6, 1296508 (2024).","DOI":"10.3389\/fdata.2023.1296508"},{"key":"2464_CR51","doi-asserted-by":"publisher","unstructured":"Kamthe, S., Assefa, S. & Deisenroth, M. Copula flows for synthetic data generation. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2101.00598 (2021).","DOI":"10.48550\/arXiv.2101.00598"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02464-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:02:39Z","timestamp":1776726159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02464-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2464"],"URL":"https:\/\/doi.org\/10.1038\/s41746-026-02464-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial or non-financial interests related to this work. Dr. Oikonomou is a co-inventor of the U.S. Patent Applications 63\/508,315 63\/177,117, a cofounder of Evidence2Health (with Dr. Khera), and has previously served as a consultant to Caristo Diagnostics Ltd (outside the present work). Dr. Oikonomou is an Associate Editor, Digital Health team at the European Health Journal. Dr. Nadkarni is an Associate Editor of npj Digital Medicine. Dr. Nadkarni was not involved in the journal\u2019s review of this article. Dr. Nadkarni is a founder of Renalytix, Pensieve, and Verici and provides consultancy services to AstraZeneca, Reata, Renalytix, Siemens Healthineer, and Variant Bio, and serves a scientific advisory board member for Renalytix and Pensieve. He also has equity in Renalytix, Pensieve, and Verici. Dr. Mortazavi reported receiving grants from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food and Drug Administration, and the US Department of Defense Advanced Research Projects Agency outside the submitted work. In addition, B.J.M. has a pending patent on predictive models using electronic health records (US20180315507A1). Dr. Khera is an Associate Editor of JAMA. He receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL167858 and K23HL153775) and the Doris Duke Charitable Foundation (under award 2022060). He also receives research support, through Yale, from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Pending Patent Applications 63\/562,335, 63\/177,117, 63\/428,569, 63\/346,610, 63\/484,426, 63\/508,315, and 63\/606,203. He is a co-founder of Ensight-AI, Inc. and Evidence2Health, health platforms to improve cardiovascular diagnosis and evidence-based cardiovascular care.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}